153 related articles for article (PubMed ID: 34378989)
1. Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy.
Laliberté F; Ashton V; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Berger JS
J Comp Eff Res; 2021 Nov; 10(16):1235-1250. PubMed ID: 34378989
[No Abstract] [Full Text] [Related]
2. Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
J Med Econ; 2021; 24(1):550-562. PubMed ID: 33910464
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
Adv Ther; 2021 Jul; 38(7):3771-3788. PubMed ID: 34031859
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
Berger JS; Ashton V; Laliberté F; Germain G; Bookhart B; Lejeune D; Boudreau J; Lefebvre P; Weir MR
Adv Ther; 2023 Mar; 40(3):1224-1241. PubMed ID: 36658454
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy.
Alberts MJ; He J; Kharat A; Ashton V
Am J Cardiovasc Drugs; 2022 Jul; 22(4):425-436. PubMed ID: 35092000
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
Curr Med Res Opin; 2021 Jun; 37(6):881-890. PubMed ID: 33733969
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study.
Mittal VS; Wu B; Song J; Milentijevic D; Ashton V; Mahajan D
Curr Med Res Opin; 2020 Apr; 36(4):529-536. PubMed ID: 31858841
[No Abstract] [Full Text] [Related]
9. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
[No Abstract] [Full Text] [Related]
10. Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting.
Mahajan D; Wu B; Song J; Milentijevic D; Ashton V; Mittal VS
Drugs Aging; 2020 Apr; 37(4):281-289. PubMed ID: 32147804
[TBL] [Abstract][Full Text] [Related]
11. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
[TBL] [Abstract][Full Text] [Related]
12. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
Curr Med Res Opin; 2020 Jul; 36(7):1081-1088. PubMed ID: 32347755
[No Abstract] [Full Text] [Related]
14. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes.
Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
J Diabetes Complications; 2021 Nov; 35(11):108029. PubMed ID: 34538715
[TBL] [Abstract][Full Text] [Related]
15. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
[TBL] [Abstract][Full Text] [Related]
17. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
[TBL] [Abstract][Full Text] [Related]
18. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1521-8. PubMed ID: 24758611
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
Peterson ED; Ashton V; Chen YW; Wu B; Spyropoulos AC
Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy.
Mentias A; Heller E; Vaughan Sarrazin M
Stroke; 2020 Jul; 51(7):2076-2086. PubMed ID: 32517580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
